Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors

Koleen J. Herlihy, Joanne P. Graham, Robert Kumpf, Amy K. Patick, Rohit Duggal, and Stephanie T. Shi*

Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, California 92121

Received 24 April 2008/Returned for modification 11 June 2008/Accepted 29 July 2008

To address the need for broad-spectrum antiviral activity characterization of hepatitis C virus (HCV) polymerase inhibitors, we created a panel of intergenotypic chimeric replicons containing nonstructural (NS) protein NS5B sequences from genotype 2b (GT2b), GT3a, GT4a, GT5a, and GT6a HCV isolates. Viral RNA extracted from non-GT1 HCV patient plasma was subjected to reverse transcription. The NS5B region was amplified by nested PCR and introduced into the corresponding region of the GT1b (Con-1) subgenomic reporter replicon by Splicing by Overlap Extension (SOEing) PCR. Stable cell lines were generated with replication-competent chimeras for in vitro antiviral activity determination of HCV nonnucleoside polymerase inhibitors (NNIs) that target different regions of the protein. Compounds that bind to the NNI2 (thiophene carboxylic acid) or NNI3 (benzothiadiazine) allosteric sites showed 8- to >1,280-fold reductions in antiviral activity against non-GT1 NS5B chimeric replicons compared to that against the GT1b subgenomic replicon. Smaller reductions in susceptibility, ranging from 0.2- to 33-fold, were observed for the inhibitor binding to the NNI1 (benzimidazole) site. The inhibitor binding to the NNI4 (benzofuran) site showed broad-spectrum antiviral activity against all chimeric replicons evaluated in this study. In conclusion, evaluation of HCV NNIs against intergenotypic chimeric replicons showed differences in activity spectrum for inhibitors that target different regions of the enzyme, some of which could be associated with specific residues that differ between GT1 and non-GT1 polymerases. Our study demonstrates the utility of chimeric replicons for broad-spectrum antiviral activity determination of HCV inhibitors.

Approximately 170 million people worldwide are infected with hepatitis C virus (HCV). Persistent infection with HCV is a primary cause of debilitating liver diseases, such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma (35, 43). HCV is a member of the Flaviviridae family with a positive-sense, single-stranded RNA genome of approximately 9.6 kb in length (5). The viral genome contains one open reading frame encoding a polyprotein of approximately 3,000 amino acids. At least 10 mature proteins result from the cleavage of the polyprotein by both cellular and viral proteases (14). The structural proteins, which include core, two envelope glycoproteins (E1 and E2), and p7, are cleaved by cellular signal peptidases (14) while the nonstructural (NS) proteins, NS2, NS3, NS4A, NS4B, NS5A, and NS5B, are cleaved by the viral NS2/3 or NS3/4A protease (10, 15). The HCV RNA genome is replicated by the RNA-dependent RNA polymerase, NS5B. Since NS5B is crucial for viral replication and has distinct features compared to those of human polymerases (21), it is a desirable target for the development of HCV therapies.

HCV isolates from around the world show substantial divergence in their genomic sequences (38). On the basis of these variations, HCV isolates have been classified into six genotypes (GT) (numbered 1 to 6) with nucleotide sequence divergence of as much as 35% (37, 49). Genotypes are further classified into subtypes, such as GT1a and GT1b, which have approximately 80% genetic similarity (37, 49). Substantial regional differences exist in the global distribution of HCV genotypes. GT1, -2, and -3 are found worldwide, of which GT1a and GT1b are the most common subtypes in the United States and Europe (50). GT1b is responsible for as many as two-thirds of the HCV cases in Japan (40). GT2 is commonly found in North America and Europe, along with a prevalence of GT3a infections among intravenous drug users in these regions (50). GT4 is prevalent in North Africa and the Middle East, whereas the less-common GT5 and GT6 appear to be confined to South Africa and Hong Kong, respectively (32, 49). In a study of 81,000 HCV patients in the United States, approximately 70% were infected with GT1, while 14 and 12% of patients were infected with GT2 and GT3, respectively, and the remaining 4% of patients were infected with GT4, -5, and -6 (T. E. Schutzbank, A. Perlina, T. Yashina, N. Wylie, and S. Sevall, presented at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 14 to 17 September 2003).

Response to the current treatment for HCV infection, pegylated interferon (IFN) and ribavirin, varies among patients infected with different genotypes. Only about 50% of patients infected with GT1 or GT4 demonstrate a sustained virologic response after treatment for 48 weeks, compared to 80 to 90% of GT2 or GT3 patients (7, 11, 29). In addition to the low
response rates associated with GT1 and GT4 infections, the pegylated IFN and ribavirin combination therapy has severe side effects that often result in high discontinuation rates and low patient compliance. Therefore, there is an unmet medical need for more effective, broad-spectrum HCV therapies with favorable safety profiles.

A significant breakthrough in HCV drug discovery was the development of the GT1b Con-1 HCV replicon system (26). Since then, replicons of GT1a and GT2a have also been generated that are amenable to cell-based screening of HCV replication inhibitors (2, 19, 20, 48). Due to the lack of replicons from other genotypes, it was not possible to determine broad-spectrum activity of HCV inhibitors in cell-based assays. In addition, replication competent GT1b, -1a, and -2a replicons are derived from a single sequence within each subtype. As a result, the variability of antiviral activity among HCV patient isolates could not be readily assessed using these reagents. To allow for broad-spectrum activity determination of HCV inhibitors against various genotypes and quasispecies encountered in the clinical setting, several chimeric replicon systems have been created that utilize replication-competent GT1b replicons as a scaffold for inserting sequences derived from patient isolates of various genotypes. Chimeric replicon systems containing NS5B, either alone or in conjunction with NS5A, from GT1a and GT1b patients were established to determine the antiviral activity spectrum of HCV polymerase inhibitors in the GT1 patient population (46). An intergenotypic chimeric replicon containing the NS5B gene from a GT2b clinical isolate in the GT1b backbone was also developed to enable the determination of susceptibility of GT2b to HCV polymerase inhibitors (9). However, generation of intergenotypic chimeric replicons that contain polymerase sequences derived from GT3, -4, -5, and -6 patient isolates has not been reported.

HCV polymerase has been the target of active research and development efforts on novel anti-HCV therapies. As is the case with other polymerases, the three-dimensional structure of the HCV polymerase resembles a right hand, complete with finger, palm, and thumb domains (1, 3, 25, 27). Several nucleoside analogues that bind to the catalytic site of the polymerase, such as NM283, R-1626, and R-7128, have been shown to be potential anti-HCV therapies (4, 39). Nonnucleoside polymerase inhibitors (NNIs) represent a more diverse class of inhibitors that bind to distinct allosteric sites in the palm, thumb, and finger domains (6, 17, 22, 23). The NN1 (benzimidazole) and NN2 (thiophene carboxylic acid) binding sites reside in the thumb domain, while the NN3 (benzothiadiazine) and NN4 (benzofuran) sites are in the palm domain of the polymerase. Since the amino acid sequences of these binding sites are more variable across genotypes than the active site, understanding of the broad-spectrum activity would be a critical step in the development of NNIs as effective HCV therapies.

In the present study, we describe the construction and characterization of an intergenotypic HCV chimeric replicon panel bearing non-GT1 polymerase sequences in a GT1b replicon backbone. The NS5B polymerase sequences were isolated from patient samples infected with GT2b, -3a, -4a, -5a, or -6a and used to replace the corresponding sequence in a highly active GT1b Con-1 reporter replicon system (12). Due to a significant reduction in the replication fitness of these chimeric replicons in transient assays, stable cell lines were created from the replication-competent intergenotypic chimeric replicons for use in susceptibility assays. All replicons showed similar susceptibilities to IFN-α and an NS3 protease inhibitor but had various levels of susceptibility to compounds that target different allosteric binding sites (NNI1 through NNI4) on NS5B. The effect of amino acid substitutions at residues 419 and 482 of the polymerase on the antiviral activity of inhibitors binding to the thumb domain (NNI1 and NNI2 sites) was also examined. Our results showed differences in activity spectrum for inhibitors that target different regions of the enzyme and indicate that the intergenotypic chimeric replicons can serve as useful tools for the discovery and development of HCV polymerase inhibitors with broad-spectrum activity.

MATERIALS AND METHODS

Cell lines and plasmids. The HuH-7 cell line was obtained from Apath LLC (St. Louis, MO). Cells were propagated in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT), 50 IU/ml penicillin, and 50 μg/ml streptomycin sulfate (Invitrogen) at 37°C with 5% CO2. All stable replicon lines were cultured using the same conditions plus the addition of 250 μg/ml G418 (Invitrogen). The GT1b Con-1 reporter replicon construct, pBB7M4 hRLuc, was constructed as described previously (12). The pBS KS plasmid was purchased from Stratagene (La Jolla, CA).

Compounds. The NS3 protease inhibitor (8) and polymerase inhibitors methylethylidene (NM107) (34), benzimidazole (13), thiophene carboxylic acid (47), benzothiadiazine (A-782759) (31), and benzofuran (HCV-796) (18) were synthesized by external vendors according to literature procedures. The structures are shown in Fig. 1.

Extraction, amplification, and sequence analysis of patient NS5B sequences. Plasma of HCV patients infected with GT2b, -3a, -4a, -5a, and -6a were purchased from Clinica (San Diego, CA) and Teragenix (Fort Lauderdale, FL) corporations. Viral RNA was extracted from 500 μl of each sample using the viral RNA mini kit (Qiagen, Valencia, CA), following the manufacturer's protocol. Reverse transcription (RT) was performed using random hexamers (IDT, Coralville, OH) and Thermoscript reverse transcriptase (Invitrogen), following the manufacturer's protocol. Two rounds of PCR were performed on the resulting cDNA using the AccumPrime Taq HiFi kit (Invitrogen) and 35 cycles of the following conditions: 94°C for 45 s, 55°C for 1 min, and 72°C for 3 min. The first round of amplification was carried out in two reaction mixtures, each containing a cocktail of primers complementary to the end of the NS5A gene and the variable region of the 3' untranslated region (UTR) (see supplemental material for primer sequences). These primers (A through D; var 1 and var 2) were designed for each genotype based on the consensus sequences generated from 2 to 14 of the published full-length polymerase sequences available in GenBank and the Los Alamos databases. Forward primers A through D were designed from the consensus sequence for each genotype. Two reverse primers were designed from the variable region sequence for each genotype (var 1 and var 2) to cover the sequence immediately downstream of the stop codon. Since sequence information for the GT6a variable region was not available, var 1 and var 2 from GT3 and GT5 were utilized in the PCRs for GT6a. The PCR products of the first-round reaction mixtures were combined and subjected to nested PCR using the two most internal primers, D and var 1. The final product was cloned into the pGEM vector by TA cloning using the pGEM-T Easy II kit (Promega, Madison, WI). Sequence analysis was performed on 10 clones for each patient, and the clone with the highest sequence homology to the patient consensus sequence was utilized for chimeric replicon construction. The amplified sequences used in this study are available in the supplemental material.

Construction of cloning vectors and chimeric replicons. The Stul or SnaBI restriction enzyme site was introduced into the variable region of the 3' UTR of pBB7M4 hRLuc using the QuikChange mutagenesis protocol (Stratagene) and primer pairs Stul.for and Stul.rev or SnaBI.for and SnaBI.rev (see supplemental material for primer sequences) to create pBB7M4 hRLuc.Stul or pBB7M4 hRLuc.SnaBI, respectively. QuikChange reactions were also carried out to introduce amino acid changes L419I and I482L for and I482L.rev to generate pBB7M4 hRLuc.L419I and pBB7M4 hRLuc.I482L. Downloaded from http://aac.asm.org on October 14, 2017 by guest
The 84-nucleotide hepatitis delta virus (HDV) ribozyme sequence (42) was introduced into pBB7M4 hRLuc-StuI and pBB7M4 hRLuc.SnaBI immediately downstream of the HCV sequence so that replicon RNA transcripts with an exact 3′ terminus of the 3′ UTR could be generated by self cleavage. The incorporation of the ribozyme was accomplished with two rounds of PCRs using Herculase DNA polymerase and PCR primers rib1.for and rib1.rev for the first round and rib2.for and rib2.rev for the second round. Both rounds of amplification were carried out for 35 cycles consisting of 95°C for 60 s, 55°C for 90 s, and 72°C for 90 s. The first-round PCR generated the fusion between a sequence from a unique NcoI site in NS5B to the end of 3′ UTR and the 5′ end sequence of the ribozyme. The resulting fragment was used as a template for the second round of PCR, which fused the HDV ribozyme sequence onto the HCV 3′ UTR. The final product was cloned into pBB7M4 hRLuc at the unique NcoI and SpeI sites. These constructs are referred to as pBB7M4 hRLuc.StuI and pBB7M4 hRLuc.SnaBI. Shuttle vectors were created for precise cloning of the patient NS5B sequences by transferring the 900 bases of the 3′ end sequence of the ribozyme from these replicons to pBS.KS at the unique EcoRI and SpeI restriction enzyme sites. These constructs are referred to as pBS.KS.StuI and pBS.KS.SnaBI.

To avoid the possible interference of the non-GT1 NS5A and 3′ UTR sequences with the replication fitness of Con-1-based chimeric replicons and their susceptibilities to polymerase inhibitors, only the NS5B region of the patient sequence was introduced into pBB7M4 hRLuc-StuI and pBB7M4 hRLuc.SnaBI immediately downstream of the HCV sequence so that replicon RNA transcripts with an exact 3′ terminus of the 3′ UTR could be generated by self cleavage. The incorporation of the ribozyme was accomplished with two rounds of PCRs using Herculase DNA polymerase and PCR primers rib1.for and rib1.rev for the first round and rib2.for and rib2.rev for the second round. Both rounds of amplification were carried out for 35 cycles consisting of 95°C for 60 s, 55°C for 90 s, and 72°C for 90 s. The first-round PCR generated the fusion between a sequence from a unique NcoI site in NS5B to the end of 3′ UTR and the 5′ end sequence of the ribozyme. The resulting fragment was used as a template for the second round of PCR, which fused the HDV ribozyme sequence onto the HCV 3′ UTR. The final product was cloned into pBB7M4 hRLuc at the unique NcoI and SpeI sites. These constructs are referred to as pBB7M4 hRLuc.StuI and pBB7M4 hRLuc.SnaBI. Shuttle vectors were created for precise cloning of the patient NS5B sequences by transferring the 900 bases of the 3′ end sequence of the ribozyme from these replicons to pBS.KS at the unique EcoRI and SpeI restriction enzyme sites. These constructs are referred to as pBS.KS.StuI and pBS.KS.SnaBI.

**Stable cell line generation.** Subgenomic replicon RNA was transcribed in vitro from replicon constructs using the MEGAscript T7 kit (Ambion, Austin, TX), following the manufacturer’s protocol. Replicon transcripts (1 to 4 μg) were electroporated into 8 × 10^6 Huh7.5 cells in a 0.4-cm cuvette using a Bio-Rad Gene Pulser II electroporator (Bio-Rad, Hercules, CA) at 270 V and 950 μF. Cells were resuspended in 10 ml growth medium and seeded in three 10-cm plates per construct at 1, 3, or 5 ml per plate. After 3 weeks of selection with 250 μg/ml of G418, colonies were picked and seeded in 96-well plates. Cells were transferred to wells with a greater surface area when confluence was reached, approximately every 2 to 4 days. Once cells reached confluence in T-25 flasks, the RLuc reporter activity was measured, and the cell line with the highest activity was scaled up for use in antiviral assays.

**Transient and stable HCV replication assay.** Huh7.5 cells were electroporated with 10 μg of in vitro replicon transcript using the electroporation conditions described above, with the exception that 220 μl was used. Electroporated cells were resuspended in Dulbecco’s modified Eagle’s medium (Invitrogen), seeded in 96-well plates at 6 × 10^5 cells per well and given a 4-h recovery period. Stable cell lines were seeded at 2 × 10^5 cells and allowed to settle for 30 min. After the recovery period, compounds were added to cells and incubated for 3 days at 37°C. Compounds were tested at half-log serial dilutions over a range of concentrations with appropriate solvent controls (compound free). HCV RNA replication was monitored by the hRLuc reporter activity in the transient or stable cell line assay using the RLuc lucerase reporter kit (Promega), following the manufacturer’s instructions in a Perkin Elmer 1430 MicroBeta JET (Perkin Elmer, Wellesley, MA). Fifty percent effective concentration (EC_{50}) values were calculated as the concentration of compound that effected a decrease in viral RNA replication (as measured by hRLuc activity) in compound-treated cells to 50% of that produced in compound-free cells. The values were determined by nonlinear regression analyses.

**RESULTS**

**Divergence of non-GT1 HCV polymerase sequences.** For each genotype, two to five patient plasma samples were subjected to RT-PCR, and one to three products were successfully amplified for further analysis (Table 1). Despite the limited number of sequences available and the lack of information for the GT6a variable region, we successfully amplified NS5B sequences from all five genotypes. To examine the quasispecies population of each non-GT1 patient NS5B amplified, the RT-PCR was carried out for 35 cycles consisting of 95°C for 60 s, 55°C for 90 s, and 72°C for 90 s. The first-round PCR generated the fusion between a sequence from a unique NcoI site in NS5B to the end of 3′ UTR and the 5′ end sequence of the ribozyme. The resulting fragment was used as a template for the second round of PCR, which fused the HDV ribozyme sequence onto the HCV 3′ UTR. The final product was cloned into pBB7M4 hRLuc at the unique NcoI and SpeI sites. These constructs are referred to as pBB7M4 hRLuc.StuI and pBB7M4 hRLuc.SnaBI. Shuttle vectors were created for precise cloning of the patient NS5B sequences by transferring the 900 bases of the 3′ end sequence of the ribozyme from these replicons to pBS.KS at the unique EcoRI and SpeI restriction enzyme sites. These constructs are referred to as pBS.KS.StuI and pBS.KS.SnaBI.

To avoid the possible interference of the non-GT1 NS5A and 3′ UTR sequences with the replication fitness of Con-1-based chimeric replicons and their susceptibilities to polymerase inhibitors, only the NS5B region of the patient sequence was introduced into pBB7M4 hRLuc-StuI and pBB7M4 hRLuc.SnaBI immediately downstream of the HCV sequence so that replicon RNA transcripts with an exact 3′ terminus of the 3′ UTR could be generated by self cleavage. The incorporation of the ribozyme was accomplished with two rounds of PCRs using Herculase DNA polymerase and PCR primers rib1.for and rib1.rev for the first round and rib2.for and rib2.rev for the second round. Both rounds of amplification were carried out for 35 cycles consisting of 95°C for 60 s, 55°C for 90 s, and 72°C for 90 s. The first-round PCR generated the fusion between a sequence from a unique NcoI site in NS5B to the end of 3′ UTR and the 5′ end sequence of the ribozyme. The resulting fragment was used as a template for the second round of PCR, which fused the HDV ribozyme sequence onto the HCV 3′ UTR. The final product was cloned into pBB7M4 hRLuc at the unique NcoI and SpeI sites. These constructs are referred to as pBB7M4 hRLuc.StuI and pBB7M4 hRLuc.SnaBI. Shuttle vectors were created for precise cloning of the patient NS5B sequences by transferring the 900 bases of the 3′ end sequence of the ribozyme from these replicons to pBS.KS at the unique EcoRI and SpeI restriction enzyme sites. These constructs are referred to as pBS.KS.StuI and pBS.KS.SnaBI.

**Stable cell line generation.** Subgenomic replicon RNA was transcribed in vitro from replicon constructs using the MEGAscript T7 kit (Ambion, Austin, TX), following the manufacturer’s protocol. Replicon transcripts (1 to 4 μg) were electroporated into 8 × 10^6 Huh7.5 cells in a 0.4-cm cuvette using a Bio-Rad Gene Pulser II electroporator (Bio-Rad, Hercules, CA) at 270 V and 950 μF. Cells were resuspended in 10 ml growth medium and seeded in three 10-cm plates per construct at 1, 3, or 5 ml per plate. After 3 weeks of selection with 250 μg/ml of G418, colonies were picked and seeded in 96-well plates. Cells were transferred to wells with a greater surface area when confluence was reached, approximately every 2 to 4 days. Once cells reached confluence in T-25 flasks, the RLuc reporter activity was measured, and the cell line with the highest activity was scaled up for use in antiviral assays.

**Transient and stable HCV replication assay.** Huh7.5 cells were electroporated with 10 μg of in vitro replicon transcript using the electroporation conditions described above, with the exception that 220 μl was used. Electroporated cells were resuspended in Dulbecco’s modified Eagle’s medium (Invitrogen), seeded in 96-well plates at 6 × 10^5 cells per well and given a 4-h recovery period. Stable cell lines were seeded at 2 × 10^5 cells and allowed to settle for 30 min. After the recovery period, compounds were added to cells and incubated for 3 days at 37°C. Compounds were tested at half-log serial dilutions over a range of concentrations with appropriate solvent controls (compound free). HCV RNA replication was monitored by the hRLuc reporter activity in the transient or stable cell line assay using the RLuc lucerase reporter kit (Promega), following the manufacturer’s instructions in a Perkin Elmer 1430 MicroBeta JET (Perkin Elmer, Wellesley, MA). Fifty percent effective concentration (EC_{50}) values were calculated as the concentration of compound that effected a decrease in viral RNA replication (as measured by hRLuc activity) in compound-treated cells to 50% of that produced in compound-free cells. The values were determined by nonlinear regression analyses.

**RESULTS**

**Divergence of non-GT1 HCV polymerase sequences.** For each genotype, two to five patient plasma samples were subjected to RT-PCR, and one to three products were successfully amplified for further analysis (Table 1). Despite the limited number of sequences available and the lack of information for the GT6a variable region, we successfully amplified NS5B sequences from all five genotypes. To examine the quasispecies population of each non-GT1 patient NS5B amplified, the RT-
PCR products were cloned into a TA vector, and 10 clones were sequenced for each patient. The percent divergence between clones of the same patient ranged from 0.2 to 3.5% at the nucleotide level and from 0 to 3.3% at the amino acid level, irrespective of the genotypes examined. The variation among the consensus sequences of the three GT2b patients ranged from 5 to 7% at the nucleotide level and 2 to 3.5% at the amino acid level, while variation between the two GT4a patients sequenced was 7% at the nucleotide level and 5% at the amino acid level. Variation between the two GT3a or GT5a sequences was only 0.2% at both the nucleotide and amino acid levels. These results indicate that the NS5B sequences from GT3a and GT5a patient samples utilized in this study were less diverse than those from the GT2b and GT4a patients.

A consensus sequence was derived from 10 clones for each patient, and the one closest to the consensus sequence derived from published sequences for that subtype was chosen for chimeric replicon construction. This method was used to most closely represent the patient sequence and to afford the chimera the best possible replication advantage. Figure 2 shows the alignment of the non-GT1 HCV NS5B amino acid sequences utilized in this study. Compared to Con-1, the divergence at the nucleotide and amino acid levels of the patient NS5B sequences used in this study ranged between 27 and 31% and 21 and 26%, respectively (Table 1).

### Replication fitness of intergenotypic NS5B chimeric replicons

To examine the replication fitness of the chimeric replicons, in vitro-transcribed RNA was electroporated into Huh7.5 cells, and the replicon RLuc reporter activity was used as an indicator of replication activity (Fig. 3A). The results showed a 60 to 80% reduction in replication activity for GT2b and GT4a chimeras, compared to Con-1, and a nearly background level of replication activity for GT3a, -5a and -6a. Similar levels of reduction in replication fitness were also observed in a colony formation assay of Huh7.5 cells electroporated with the intergenotypic chimeras (Fig. 3B). The number of colonies produced by the GT2b and GT4a NS5B chimeras was reduced by approximately 50% and 30%, respectively, compared to the Con-1 replicon. Both GT3a and GT5a formed stable colonies despite the nearly background levels of replication in the transient assay, but the total number of colonies was dramatically reduced compared to those for Con-1 by approximately 80 and 98%, respectively. A few colonies were observed for the GT6a chimeric replicon, but none survived to become stable cell lines. The significant reduction in the replication fitness of chimeric replicons containing intergenotypic sequences was consistent with previous reports (9, 28).

### Generation of stable cell lines

On account of the low level of replication observed for the intergenotypic chimeric replicons in the transient replication assay, stable cell lines were isolated and scaled up for use in susceptibility assays. Between 5 and 10 individual lines were expanded for each genotype, and the line with the highest RLuc activity and optimal growth kinetics was used for antiviral activity determinations of known HCV inhibitors. With the exception of GT6a, stable cell lines with high reporter activities (>120,000 relative light units) were obtained for all intergenotypic chimeric replicons. To identify any amino acid changes that may have allowed for cell culture adaptation and increases in the replication efficiency of the chimeric replicons, the NS5B region was amplified and sequenced from the total cellular RNA of the stable lines. No nucleotide sequence changes that resulted in amino acid changes were observed in the NS5B region of any of the chimeric replicon cell lines. It is possible, however, that sequence changes may have occurred outside of the NS5B region. Our attempt in generating a stable cell line from the GT6a NS5B chimeric replicon was not successful. Another chimera was generated with a different NS5B sequence from the same patient, but the alternative sequence did not result in increased replication efficiency or the successful generation of a stable cell line.

### In vitro antiviral activities of HCV inhibitors against intergenotypic chimeric replicons

Susceptibility assays were carried out for stable lines containing the non-GT1 NS5B chimeric replicons in order to determine the in vitro antiviral activities of HCV inhibitors. As expected, there were no significant changes in the antiviral activity of IFN or a macrocyclic protease inhibitor (Fig. 1) against any of the intergenotypic chimeric replicons compared to that against Con-1 (Table 2). The protease inhibitor had a 112-fold reduction in activity against the GT2a JFH1 subgenomic replicon, which is consistent with previously reported results (41, 45).

A set of polymerase inhibitors that bind to different regions of the enzyme (Fig. 1) was tested against the intergenotypic chimeric replicon panel in stable cell lines (Table 2) in order to understand the broad-spectrum activity of these compounds. The nucleoside polymerase inhibitor, NM107, exhibited similar antiviral activity across all genotypes evaluated (fold change values, ≤4), consistent with the notion that nucleoside inhibitors targeting the active site have broad-spectrum activities against polymerases of different genotypes. A polymerase inhibitor from the benzimidazole series that interacts with the NN11-binding site of the enzyme displayed an 8- to 33-fold reduction in activity against GT2a and GT2b compared to Con-1, but no reduction in activity against GT3a, 4a, and 5a. Another NNI, a thiophene carboxylic acid that binds to the NN12 pocket, showed a modest reduction in antiviral activity against GT5a (8-fold) but lost considerable activity against GT4a (88-fold), -2b, and -3a (>1,280-fold). The benzothiadiazine polymerase inhibitor that binds to the NN13 region, A-782759, showed a significant reduction in activity against all non-GT1 chimeric replicons, with fold reductions in EC50 val-

<table>
<thead>
<tr>
<th>GT</th>
<th>No. of samples subjected to RT-PCR</th>
<th>No. of samples amplified by RT-PCR</th>
<th>Divergence of the NS5B sequences from Con-1a</th>
<th>% Nucleotide divergence</th>
<th>% Amino acid divergence</th>
</tr>
</thead>
<tbody>
<tr>
<td>2b</td>
<td>5</td>
<td>3</td>
<td>31</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>3a</td>
<td>2</td>
<td>2</td>
<td>28</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>4a</td>
<td>5</td>
<td>2</td>
<td>29</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>5a</td>
<td>2</td>
<td>2</td>
<td>28</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>6a</td>
<td>3</td>
<td>1</td>
<td>27</td>
<td>21</td>
<td></td>
</tr>
</tbody>
</table>

a RNA was extracted from patient plasma samples using the Qiagen viral RNA minikit. RT-PCR was performed on each sample to amplify the NS5B gene of HCV. The number of samples successfully amplified varies by genotype.

b Sequence comparison was performed on the patient NS5B sequences used to construct the replication-competent chimeric replicons that produced antiviral results shown in this study (except for GT6a).
FIG. 2. Alignment of the HCV polymerase sequences utilized in this study. Amino acid residues 419 and 482, located in the thumb domain of the polymerase (25), are highlighted in gray boxes. The key amino acid residues that are present in the active and NNI-binding sites are also highlighted.
FIG. 3. Replication fitness of intergenotypic chimeric replicons in transient replication (A) and colony formation (B) assays. (A) HCV reporter replicon constructs were electroporated into Huh7.5 cells, seeded in 96-well plates at 6 × 10^4 cells/well, and cultured for 3 days before RLuc activity was measured. Results represent the averages of duplicate values. FC, fold change in EC50 over that of the wild-type Con-1 replicon.

TABLE 2. In vitro antiviral activity of HCV inhibitors against intergenotypic chimeric replicons

<table>
<thead>
<tr>
<th>Replicon construct</th>
<th>RLuc count (10^3)</th>
<th>Nucleoside active site</th>
<th>Benzoimidazole (NNI1) EC50 (µM)</th>
<th>Thiopeptide carboxylic acid (NNI2) EC50 (µM)</th>
<th>Benzothiazidaine (NNI3) EC50 (µM)</th>
<th>Benzofuran (NNI4) EC50 (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Con-1</td>
<td>490</td>
<td>1.3</td>
<td>0.90</td>
<td>0.025</td>
<td>0.033</td>
<td>0.042</td>
</tr>
<tr>
<td>GT1a, H77</td>
<td>450</td>
<td>1.1</td>
<td>1.025</td>
<td>0.025</td>
<td>0.033</td>
<td>0.042</td>
</tr>
<tr>
<td>GT2a, JFH1</td>
<td>378</td>
<td>1.1</td>
<td>0.90</td>
<td>0.025</td>
<td>0.033</td>
<td>0.042</td>
</tr>
<tr>
<td>GT3aNS5B, Con-1</td>
<td>120</td>
<td>1.1</td>
<td>0.90</td>
<td>0.025</td>
<td>0.033</td>
<td>0.042</td>
</tr>
<tr>
<td>GT4aNS5B, Con-1</td>
<td>500</td>
<td>1.1</td>
<td>0.90</td>
<td>0.025</td>
<td>0.033</td>
<td>0.042</td>
</tr>
<tr>
<td>GT5aNS5B, Con-1</td>
<td>350</td>
<td>1.1</td>
<td>0.90</td>
<td>0.025</td>
<td>0.033</td>
<td>0.042</td>
</tr>
</tbody>
</table>

*The susceptibilities of the chimeric replicon cell lines to HCV inhibitors were evaluated in the reporter replicon assay. Cells were exposed to compounds for 3 days before RLuc activity was determined. Results represent the averages of duplicate values. FC, fold change in EC50 over that of the wild-type Con-1 replicon.
role in determining the susceptibilities of HCV polymerases to certain inhibitors binding to either the NNI1 or NNI2 pocket.

**DISCUSSION**

In the present study, chimeric replicons that contained the NS5B genes from patients infected with GT2b, -3a, -4a, -5a, and -6a in the GT1b Con-1 backbone were constructed. The fitness of the chimeras was significantly impaired in comparison to the Con-1 replicon in both transient and colony formation assays. The antiviral activities of inhibitors binding to each of the four allosteric binding pockets of the polymerase (Fig. 4) were determined using stable cell lines created from each of the replication-competent non-GT1 NS5B chimeras. This evaluation revealed differences in the activity spectrum for specific inhibitors that target different regions of the polymerase enzyme (Table 2). This study further validates the utility of chimeric replicons for broad-spectrum antiviral activity determination of HCV polymerase inhibitors.

Previous studies have utilized chimeric replicons constructed using GT1b as a scaffold for inserting sequences amplified from infected patient samples. Systems expressing polymerase sequences from GT1 and GT2 patients have been previously reported (9, 24, 46). In particular, chimeric replicons with NS5B from GT1a and GT1b patients were developed to determine the antiviral activities of clinical candidates against a panel of GT1 clinical isolates (28, 30, 46). Therefore, chimeric replicons may be a useful tool for identifying broad-spectrum HCV inhibitors of non-GT1 targets that have not yet been developed as full-length replicons. One caveat to these previous studies is that the chimeric replicons often contain additional patient-derived sequences flanking NS5B, which may complicate interpretations of results for NS5B inhibitors. In addition, only a limited number of genotypes were evaluated in previous studies. To date, there have been no reports of GT4a or GT5a NS5B chimeric replicons. This study describes for the first time a more comprehensive panel of chimeric replicons that contains patient-derived NS5B sequences representing GT1 to GT5. Furthermore, the chimeric replicons generated for the current study contain exact NS5B-coding region replacements, allowing for the interrogation of NS5B inhibitors without the influence of adjacent sequences derived from patient isolates. Our expectation is that this may allow for better correlations of activity with biochemical assays. Alternatively, one limitation of the chimeric replicon system presented here or in previous studies is that any differential effects on antiviral activity of RNA-protein or protein-protein interactions that occur between the patient-derived NS5B and Con-1 RNA proteins in the context of replication complexes cannot be fully evaluated.

Clonal sequencing analysis of the NS5B region was performed on 10 clones from each patient sample. Although the sample set examined was relatively small, it is clear that the divergence between GT1 and non-GT1 NS5B amino acid sequences ranged from 25 to 31%, consistent with those previously reported in the literature. The GT6a NS5B is more closely related to the Con-1 sequence than to the other non-GT1 sequences, but the GT6a chimera was not able to maintain the level of replication needed to create a stable cell line. The GT3a and GT5a chimeras also had severely impaired fitness, as shown in the transient replication and colony formation assays. In contrast, the GT2b and GT4a chimeras reached viable levels of replication even in the transient assay and produced a large number of colonies compared to other genotypes. The GT4a chimera had the highest level of replication fitness despite the relatively higher divergence of GT4a NS5B from the Con-1 sequence. These results suggest that specific amino acid residues of the non-GT1 NS5B sequence, rather than its overall sequence similarity to Con-1, may determine the fitness of the intergenotypic chimeric replicons. Despite the low replication fitness observed in transient assays,
stable cell lines that produced high levels of reporter activity were successfully generated for all chimeric replicons, except for GT6a (Table 2). Two different patient sequences were tested for stable cell line generation for both GT3a and GT5a chimeras, and only one from each genotype was replication competent. These results show that not all patient NS5B sequences are viable in the Con-1 backbone due to sequence incompatibility. The NS5B sequence from two clones of the only GT6a patient successfully amplified were used to generate chimeric replicons, but neither of these sequences supported stable cell line formation under various conditions. Future attempts to establish this chimera would include obtaining more GT6a patient samples or cloning the GT6a NS5B sequences into a different replicon backbone, such as the GT1b BK and the GT2a JFH1 subgenomic replicons (28).

Four allosteric binding pockets have been identified in the HCV polymerase protein (Fig. 4), and several chemical series have been shown to interact with each of these pockets by in vitro resistance and crystallographic studies (23, 27, 33). The results in Table 2 clearly show that the NNI1 binder tested in this study has comparable activity against GT1,-3a,-4a, and -5a but reduced activity against GT2a and GT2b, consistent with results generated in enzymatic assays. No variations were observed in any of the non-GT1 chimeras tested at amino acid residue 495, which was shown to be the hot spot for resistance changes (22, 44). The thiopehene carboxylic acid compound that binds to the NN21E pocket showed significantly reduced activity against the non-GT1 polymerases tested as indicated by up to ~1,280-fold changes in the EC_{50} values compared to Con-1. However, the NN21E binder retained considerable activity against GT5a with only an eightfold change in EC_{50}. An alignment of the patient sequences utilized in this study showed that GT2,-3a, and -4a encoded Ile and Leu residues at NS5B positions 419 and 482, respectively, while the Con-1 and GT5a sequences encoded Leu and Ile residues at positions 419 and 482, respectively. When the L419I and I482L substitutions were introduced into the Con-1 replicon and tested in a transient assay, shifts in antiviral activity similar to those measured for GT2, -3a, and -4a were observed. These results suggest that the I419 and L482 residues are responsible for the loss in antiviral activity of this compound against GT2, -3a, and -4a polymerase sequences. Compounds that bind to the NN3 pocket have been shown to interact with the M414 residue by in vitro resistance studies (31, 33). Instead of M414, which was observed in GT1 and GT5a NS5B, the GT2 and GT4a NS5B sequences used in this study contain Gin and Val at amino acid position 414, respectively, which may contribute to the large fold changes in activity seen with A-782759 against the GT2b and GT4a chimeras. The GT3a NS5B has a Met at residue 414, and the basis of the >970-fold reduction in activity against this chimera with A-782759 is not clear at this time. In all cases, the resistance mutations described here are likely to be only one of the factors contributing to the changes in antiviral activity seen with the intergenotypic chimeras. HCV-796 showed broad-spectrum activity with a less than threefold decrease in antiviral activity against all genotypes tested. It has been previously reported that naturally occurring polymorphism at residue 316 could result in differential susceptibility to HCV-796 (36). In all sequences used here, the amino acid at residue 316 is a Cys. Since only one chemotype for each binding site was tested in this study, we cannot rule out that different chemical classes targeting the same binding site may behave differently.

The evaluation of HCV polymerase inhibitors against intergenotypic chimeric replicons showed differences in activity spectrum for specific inhibitors that target different regions of the polymerase enzyme. The results presented in this study suggest that evaluating the antiviral activities of HCV polymerase inhibitors against a panel of non-GT1 NS5B chimeric replicons can give insight into the relationship between sequence changes and resistance mutations for compounds that bind to the four different allosteric pockets of the polymerase protein. This study demonstrates the utility of chimeric replicons for broad-spectrum activity determination of HCV inhibitors.

ACKNOWLEDGMENTS

We acknowledge all members of the HCV polymerase project team at Pfizer PGRD La Jolla Laboratories. We are grateful to members of the virology department, particularly Wade Blair, for their scientific input and critical review of the paper. We also thank student assistants Ashley Roth and Amy Chan for their dedication and hard work.

REFERENCES

INTERGENOTYPIC HCV POLYMERASE CHIMERIC REPLICONS

3531


